These metabolic pathways are involved in the pathogenesis or immune response of HCC (Wang et al., 2016; Ma et al., 2018; Liu et al., 2020); thus, RNF157-AS1 may regulate HCC progression and induce doxorubicin resistance by interacting with these metabolic pathways. Here, RNF157 is linked to hepatocellular carcinoma.